drugset / Trial / NCT06486142
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.
Timeline
- Start
- 2022-09-21
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Afatinib | Small molecule | — | — |
| Comparator | DACOMITINIB ANHYDROUS | Small molecule | — | — |
| Comparator | Osimertinib | Small molecule | — | — |